Organovo (NASDAQ:ONVO – Get Free Report) is expected to announce its earnings results before the market opens on Thursday, February 13th. Analysts expect the company to announce earnings of ($0.21) per share and revenue of $0.05 million for the quarter.
Organovo (NASDAQ:ONVO – Get Free Report) last posted its quarterly earnings results on Friday, November 8th. The medical research company reported ($0.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.12. Organovo had a negative return on equity of 249.28% and a negative net margin of 12,176.70%. The business had revenue of $0.03 million for the quarter, compared to the consensus estimate of $0.04 million. On average, analysts expect Organovo to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Organovo Stock Up 1.4 %
Shares of NASDAQ:ONVO opened at $0.34 on Thursday. Organovo has a twelve month low of $0.32 and a twelve month high of $1.74. The stock’s 50 day moving average is $0.40 and its 200-day moving average is $0.46. The firm has a market capitalization of $5.28 million, a price-to-earnings ratio of -0.32 and a beta of 0.54.
Wall Street Analysts Forecast Growth
Check Out Our Latest Stock Report on Organovo
Organovo Company Profile
Organovo Holdings, Inc, a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.
Featured Articles
- Five stocks we like better than Organovo
- What is an Earnings Surprise?
- 3 Must-Have ETFs Set to Dominate This Quarter
- What is a Special Dividend?
- Seeking Stability? These 3 Stocks Offer Strong Potential
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Trade War Bargain Stocks: Top 3 Picks Too Good to Pass Up
Receive News & Ratings for Organovo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organovo and related companies with MarketBeat.com's FREE daily email newsletter.